On June 9, WuXi Biologics fell 3.09% in regular trading, trading at HK$28.9/share, with trading volume of HK$337 million. The decline marks a continuation of heavy selling pressure, with the stock having already dropped 7.21% in the prior session and accumulating over 13% in losses since June 3.

The broader Life Sciences Tools and Services sector remains under pressure as concerns over US biosecurity legislation persist. On June 2, the US House China Committee formally introduced the Biotechnology Investment National Security Act (BINSA), reviving fears of regulatory restrictions on Chinese CXO companies. WuXi Biologics has reportedly been exploring the transfer of overseas assets to mitigate geopolitical risk exposure. Among sector peers, WuXi AppTec fell 4.62%, WuXi XDC dropped 3.68%, GenScript BioScience declined 4.22%, XtalPi lost 2.82%, and Insilico fell 1.73%.

Despite the selloff, the company has conducted consecutive buybacks totaling approximately HK$399 million since June 3, repurchasing 12.61 million shares. CICC recently maintained its Outperform rating with a HK$48 target price, implying significant upside from current levels.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)